Estropipate is a Medicine belongs to Estrogen group whose information about Brand can be referenced from   Book : Martindale    Page : 2307   Edition : 37  

  ►   Brandname : Harmogen, Ogen, Ortho-Est
  ►  Strength : Tablet with 0.625 mg.  Tablet with 1.25 mg.  Tablet with 2.5 mg.  Tablet with 5 mg.  Cream with 1.5 mg/gm. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 740   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral, Topical
Reference :-   Book : Martindale    Page : 2307   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Menopausal HRT Oral 0.75 3 mg Tablet Dose: given daily cyclically or continuously; doses up to 6 mg daily have also been given cyclically
2 Menopausal atrophic vaginitis Topical 2 4 gm Cream Dose: Applied daily.
3 Female hypogonadism Oral 1.5 3 mg Tablet Dose: Given daily, daily, in a cyclical regimen; higher doses of up to 9 mg daily given cyclically have also been used.
4 Castration Oral 1.5 3 mg Tablet Dose: Given daily, daily, in a cyclical regimen; higher doses of up to 9 mg daily given cyclically have also been used.
5 Primary ovarian failure Oral 1.5 3 mg Tablet Dose: Given daily, daily, in a cyclical regimen; higher doses of up to 9 mg daily given cyclically have also been used.

Ref :-  Book : Martindale    Page : 2307   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
►  Side Effect : Nausea, Vomiting, Abdominal cramp, Bloating, Weight changes, Breast enlargement, Tenderness, Cholestatic jaundice, Glucose intolerance, Rashes, Chloasma, Changes in libido, Migraine, Dizziness, Depression, mood changes, Headache, Leg cramps, Vaginal candidiasis, Premenstrual like syndrome, Sodium and fluid retention, Altered blood lipids, Decreased tolerance of contact lense
Ref :-   Book : Martindale    Page : 2275,2307   Edition : 37.  

►  Drug Interaction : Drug interaction of Estropipate is with , , Alcohol, , Oral Contraceptive,  Griseofulvin , Rifampicin , Modafinil , Phenytoin , Levothyroxine
Ref :-   Book : Martindale    Page : 2271,2280,2307   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Drugs that increase the hepatic metabolism of oestrogens and progestogens have been associated with failure of the combined oral contraceptive. Enzyme-inducing drugs can cause combined oral contraceptives to fail by increasing their metabolism and clearance. This effect is well established for a number of antiepileptics, griseofulvin, and rifamycin antibacterials, and has also been suggested for some antivirals and for modafinil. Although less well documented, these interactions would also be expected to apply to progestogen-only contraceptives. Although oral contraceptives alter the effects of a number of drugs, the lower doses of oestrogens used in HRT are considered less likely to induce interactions, although the possibility remains. Both alcohol consumption and HRT are risk factors for breast cancer. Phenytoin was reported to reduce the effect of conjugated oestrogens in a menopausal woman. Increased doses of levothyroxine may be needed in hypothyroid women who receive oestrogens for postmenopausal HRT. Antoxidant effect of ascorbic acid might reverse the oxidation of oestrogens.
Ref :-   Book : Martindale    Page : 2271,2280,2307   Edition : 37.  

►  Contraindication : Oestrogen- dependent neoplasms, Active liver disease, Rotor syndromes, Women with untreated endometrial hyperplasia, HRT should be avoided in women with active thrombophlebitis or thromboembolic disease; it should not be given to those with a history of recurrent thromboembolism unless they are already receiving anticoagulant treatment, HRT should not be given to those with undiagnosed abnormal vaginal bleeding, and abnormal vaginal bleeding during therapy should be investigated, HRT should be used with caution in women with antiphospholipid antibodies or predisposing factors to thromboembolism and in migraine, a history of breast nodules or fibrocystic disease, uterine fibroids, or a history of endometriosis, HRT should also be used with caution in women with diabetes because of the increased risk of heart disease, Consideration should be given to temporarily stopping HRT 4 to 6 weeks before elective surgery, Oestrogens should be used with caution in children because premature closure of the epiphyses may occur resulting in inhibited linear growth and small stature, Oestrogens have been reported to interfere with some diagnostic tests such as those for thyroid function and glucose tolerance, Women using topical formulations should be take care to avoid skin-to-skin contact with others for an appropriate time after application, according to advice in licensed product information
Ref :-   Book : Martindale    Page : 2279,2303-2304,2307   Edition : 37.  
  ►  Mechanism of Action :   Estropipate is a semisynthetic conjugate of estrone with piperazine. Plasma estrogens in the blood and interstitial fluid are bound to SHBG, from which they dissociate to enter the cell and bind to their receptor. Two genes code for two estrogen receptor isoforms, α and β, which are members of the superfamily of steroid, sterol, retinoic acid, and thyroid receptors. Binding of the hormone to its receptor alters its conformation and releases it from the stabilizing proteins (predominantly Hsp90). The receptor-hormone complex forms homodimers that bind to a specific sequence of nucleotides called estrogen response elements (EREs) in the promoters of various genes and regulate their transcription. Ref: Martindale pg no 2307 ed 37.
Ref :-   Book : Basic & Clinical pharmacology    Page : 718-719   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Bellabonna with Another pathway.  

  ►  Pathway with its reference as follows :-
  • Increasing anticholinergic activity of tricyclic antidepressants . --- ( Duke, J. (2002). Handbook of Medicinal Herbs (2nd ed.). Boca Raton London New York Washington ,D.C. )

  •   ►  URL --
  • .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   NA

    ►    Plasma Half-life :   Min value :-   NA    Max value :-   NA

    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA